To date, three small molecule tyrosine kinase inhibitors (TKIs, EGFR–gefitinib and erlotinib; EGFR/HER2–lapatinib) and four monoclonal antibodies (mAbs, EGFR–cetuximab and panitumumab; HER2–trastuzumab and pertuxumab) have been FDA-approved for use in breast, colorectal, head and neck, non-small cell lung, and pancreatic cancers. The gene discussed is EGFR; the disease is familial pancreatic carcinoma.